Area of Interest

We are addressing myopia comprehensively by studying the patient journey, understanding how a patient feels from early to late stage with the disease and developing the best-in-class therapeutic options to address patients and their families‘ needs. To protect children from the risk of vision problems with myopia, educational activities in collaboration with key opinion leaders (KOLs) are extremely important. Our initiatives include developing a low concentration atropine formulation along with proper disease awareness activities, a next-generation drug with better efficacy and safety, and to create greater value for patients through collaboration with external partners during drug discovery.
 

Ptosis is a unilateral or bilateral drooping of the upper eyelid that usually occurs from a partial or complete dysfunction of the muscles that elevate the upper eyelid. It can lead to decreased visual fields and lower quality of life (QOL) for patients. Tens of millions of adults are suffering from ptosis globally^*2,3. We are developing a novel ophthalmic formulation of oxymetazoline, a direct-acting alpha adrenergic receptor agonist, for the treatment of acquired ptosis. It is reported to selectively target Müller’s muscle and elevate the upper eyelid when administered to the eye.